UNSPSC 51292909: Lofepramine

This classification denotes an antidepressant agent with the molecular formula C26H27ClN2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OCA4JT7PAW, chemically known as 5,6-dihydro-n-(3-(dimethylamino)propyl)-11h-dibenz(b,e)azepine but generally known as lofepramine, which bears US NIH Compound Identifier 3696. European Medicines Agency schedules Lofepramine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08557MIG. The term LOFEPRAMINE is an International Non-Proprietary Name.

UNSPSC 51292909 Lofepramine, a Commodity code, shows minimal recent activity aligned with its nominal scope. State and local governments buying under this code are sourcing pharmaceutical products, but the recent solicitations tagged to it span naloxone and drug deactivation systems, therapeutic pharmacy initiatives for direct-to-manufacturer prescription fulfillment, and generic multi-source pharmaceuticals and OTC products — a broad and functionally diverse range that does not center on lofepramine specifically. The issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multiple states (Minnesota Multistate Cooperative Purchasing Alliance, MMCAP). The code does not show standout repeat buyers or a concentrated procurement pattern.

Recent opportunities span Florida, Texas, and Minnesota through cooperative arrangements extending to Oregon. The Seminole County solicitation (IFB 60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding. The Texas HHS Commission issued an RFI (HHS0017013, due April 3, 2026) to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP (S1070000015802, due March 26, 2026) to establish multi-award contracts for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities. The mismatch between the lofepramine code designation and the actual procurement scope suggests limited relevance of this code to current state and local pharmaceutical sourcing activity.